
Bloating is not normal: How enzyme-based supplements can help reduce water retention
A roti, sabzi and a little bowl of rice is a simple home cooked lunch that you take. No epacmiums, no massiness. However, in 30 minutes, you begin to feel uncomfortable in your stomach.
It feels pressure and probably some burping and you feel the need to loosen the belt around the waist.
Or you pick up a sandwich at lunchtime when the schedules are too tight to sit down to eat or when you are too busy doing something so you end up coming back to an uneasy sluggish stomach along with a bloated belly.
It occurs in all of us. And so we sweep it under the rug saying that it is just typical bloating, but you know what, bloating is not supposed to be normal.
It is the indicator of the fact that your digestive system is overloaded and it might be as minor as the fact that your body is not producing the sufficient number of digestive enzymes.
What Really Causes Bloating?
Bloating happens when food fails to be entirely broken down and resorts to fermenting in your gut thereby producing excess gas. The result? Bloating, discomfort, heavy abdomen, and even noticeable abdominal distension.
Common triggers include:
● Dairy or high-fat foods
● Lentils and legumes
● Eating too quickly or while stressed
● Skipping meals and then overeating
● Low digestive enzyme production
Effective proteins are digestive enzymes which convert food material into nutrients that your body can utilize.
Under low levels of these enzymes e.g. with age or stress or even unhealthy diets your digestive process becomes slow and bloating makes it its common side effect after eating a meal.
Where
Enzyme-Based Supplements
Come In
This can be filled using enzyme based supplements. Such supplements have super-concentrated versions of the same enzymes that your body makes to break down food such as amylase (carbs), protease (proteins), lipase (fats), and lactase (dairy).
Here's how they help reduce bloating:
● Break Down Complex Food : Indian meals contain a lot of starch, spices, milk products, and fiber. These can be hydrolyzed easily using a blend of enzymes in order to minimize chances of fermentation and gas.
● Act Fast at the Source : Unlike ingesting antacids or gas-relief pillines which only work once you feel bad, enzymes do their work at the beginning of the digestive tract thus avoiding bloating before it happens.
● Improve Nutrient Absorption : The more thoroughly food is digested, the more vitamins, minerals and energy can be absorbed by your body leaving you feeling lighter and more nourished after eating.
● Support Gut Balance Over Time : The enzyme supplementation can help gradually balance gut activity over time which helps in improving the general digestive efficiency, which is a major problem faced by many people on a routine basis.
How to Use Enzyme Supplements Effectively
Best taken with meals, especially if they are rich, heavy or include known problem causing foods such as dairy or gluten. They're safe to use every day and can be used for longer periods or just when you need them such as when you're eating out, traveling or you have to eat differently such as with festivals.
Remember: prevention, not just treatment is the aim. That, in part, differentiates enzyme supplements from typical gas relief over-the-counter solutions.
Listen to Your Gut
Bloating can be easily overlooked and taken as an inconvenience of the body, though it is your guts telling you something is wrong. Rather than just making discomfort normal, we should think about digestion and be helpful in it.
The solution is not only to banish the bloat, but in the process get your body digesting, absorbing, and feeling its best all day long, and the enzyme-based supplements do exactly that.
It is not supposed to make you feel worse when you have eaten.
And bloating? The same does not even have to be your routine.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Hindu
20 minutes ago
- The Hindu
AINU launches new centre in Hyderabad covering various sub-specialities
The Asian Institute of Nephrology and Urology (AINU), launched its new centre in Banjara Hills here on Monday. The hospital has a capacity of 150 beds. The centre features four operating rooms, 34 dialysis stations and advanced robotic surgical technology, enabling complex urology and nephrology procedures with greater precision. The hospital also has eight centres of excellence, covering sub-specialities such as female urology, uro-oncology and robotic surgery, paediatric urology, reconstructive urology and andrology. The burden of urological diseases is rising sharply in India due to lifestyle disorders such as hypertension, obesity and diabetes, coupled with increased life expectancy. 'Prostate cancer is now the second most common cancer among Indian men, growing at 2.5% annually, and 50 to 60% of men over 60 suffer from benign prostatic enlargement,' said AINU manging director Mallikarjuna. He added that 25 years ago, urology was largely limited to treating kidney stones and enlarged prostates. Today, the scope includes advanced cancer care, complex reconstructions, paediatric interventions, female urology and robotic surgeries. 'One doctor cannot be perfect in every area, so we have created dedicated teams focused solely on one sub-speciality, performing the same surgeries repeatedly. This results in faster procedures, fewer complications, better outcomes and ultimately lower costs for patients,' he added.


Economic Times
an hour ago
- Economic Times
India clears Roche's 7-minute cancer injection Tecentriq for patients, with Phase IV trial condition
Synopsis Roche has received clearance to import and market Atezolizumab injection (Tecentriq) for subcutaneous administration in India, potentially reducing cancer treatment time and costs. The approval, granted by a technical committee, requires Roche to conduct a Phase IV clinical trial in India. This new route offers a faster, more convenient option for patients, with administration possible outside of hospitals. Roche Gets Approval to Import Key Cancer Injection for Domestic Mkt New Delhi: The technical committee constituted for supervising clinical trials on new chemical entities has cleared Swiss drug major Roche to import and market cancer drug Atezolizumab injection (Tecentriq) through subcutaneous (SC) route-under the skin injection for Indian decisions is expected to provide relief to patients in the contry as the new subcutaneous injections will cut treatment time to nearly seven minutes from the 30-60 minutes in the standard intravenous (IV) infusion, besides saving on costs. The panel's permission has been given with a condition that the company would conduct a Phase IV clinical trial in India. "Switching from intravenous (IV) to subcutaneous (SC) administration of Atezolizumab can potentially reduce costs due to decreased healthcare professional time and improved patient convenience," a government official told ET. "Tecentriq may be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient's home," he added. Atezolizumab is an immunotherapy called an immune checkpoint inhibitor, which blocks the immune system's natural brakes to help immune cells fight technical committee under the Director General of Health Services (DGHS) was formed in 2013 following the directions of the Supreme a recent meeting, Roche presented the proposal for grant of permission to import and market the drug product Atezolizumab injection (Tecentriq®) 1875 mg/15 mL vial for subcutaneous administration for the following indications with the request of local Phase III clinical trial waiver and commitment to conduct a Phase IV trial in is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. It is a monotherapy for the first line treatment of patients of metastatic committee noted the pharmacokinetic-pharmacodynamic or PK/PD results of Asian & non-Asian population from the global clinical study for the ethnic differences in the PK parameters in the study. The committee further noted that firm has received the USFDA approval for the SC route on committee also asked the company to submit Phase IV clinical trial protocol to CDSCO within three months of grant of marketing authorisation.


Time of India
an hour ago
- Time of India
India clears Roche's 7-minute cancer injection Tecentriq for patients, with Phase IV trial condition
New Delhi: The technical committee constituted for supervising clinical trials on new chemical entities has cleared Swiss drug major Roche to import and market cancer drug Atezolizumab injection ( Tecentriq ) through subcutaneous (SC) route-under the skin injection for Indian patients. The decisions is expected to provide relief to patients in the contry as the new subcutaneous injections will cut treatment time to nearly seven minutes from the 30-60 minutes in the standard intravenous (IV) infusion, besides saving on costs. The panel's permission has been given with a condition that the company would conduct a Phase IV clinical trial in India. "Switching from intravenous (IV) to subcutaneous (SC) administration of Atezolizumab can potentially reduce costs due to decreased healthcare professional time and improved patient convenience," a government official told ET. "Tecentriq may be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient's home," he added. Atezolizumab is an immunotherapy called an immune checkpoint inhibitor, which blocks the immune system's natural brakes to help immune cells fight cancer. The technical committee under the Director General of Health Services (DGHS) was formed in 2013 following the directions of the Supreme Court. In a recent meeting, Roche presented the proposal for grant of permission to import and market the drug product Atezolizumab injection (Tecentriq®) 1875 mg/15 mL vial for subcutaneous administration for the following indications with the request of local Phase III clinical trial waiver and commitment to conduct a Phase IV trial in India. Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. It is a monotherapy for the first line treatment of patients of metastatic NSCLC. The committee noted the pharmacokinetic-pharmacodynamic or PK/PD results of Asian & non-Asian population from the global clinical study for the ethnic differences in the PK parameters in the study. The committee further noted that firm has received the USFDA approval for the SC route on 12.09.2024. The committee also asked the company to submit Phase IV clinical trial protocol to CDSCO within three months of grant of marketing authorisation.